Evidence map›Paper›PMID 27244898›Full record

ArticleOncotarget2016

Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.

Attila Szendrői, A Marcell Szász, Magdolna Kardos, Anna-Mária Tőkés, Roni Idan, Miklós Szűcs, Janina Kulka, Péter Nyirády, Miklós Szendrői, Zoltán Szállási and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Pan-Cancer Analysis Based onFrontiers in oncology · 2022
    Article
  4. Review
  5. Review
  6. Article
  7. The Journal of biological chemistry · 2020
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Attila SzendrőiDepartment of Urology, Semmelweis University, Budapest 1082, Hungary.
A Marcell Szász2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Magdolna Kardos2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Anna-Mária Tőkés2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Roni Idan2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Miklós SzűcsDepartment of Urology, Semmelweis University, Budapest 1082, Hungary.
Janina Kulka2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Péter NyirádyDepartment of Urology, Semmelweis University, Budapest 1082, Hungary.
Miklós SzendrőiDepartment of Orthopedics, Semmelweis University, Budapest 1113, Hungary.
Zoltán SzállásiChildren's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA.
Balázs GyőrffyMTA-TTK Lendület Cancer Biomarker Research Group, Budapest 1117, Hungary.
József Tímár2nd Department of Pathology, Semmelweis University, Budapest 1091, Hungary.
Semmelweis University · HUHUN-REN Research Centre for Natural Sciences · HUTechnical University of Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrognostic markers of bone metastatic clear cell renal cell cancer (ccRCC) are poorly established. We tested prognostic value of HIF1α/HIF2α and their selected target genes in primary tumors and corresponding bone metastases.

resultsExpression of HIF2α was lower in mRCC both at mRNA and protein levels (p/mRNA/=0.011, p/protein/=0.001) while HIF1α was similar to nmRCC. At the protein level, CAIX, GAPDH and GLUT1 were increased in mRCC. In all primary RCCs, low HIF2α and high HIF1α as well as CAIX, GAPDH and GLUT1 expressions correlated with adverse prognosis, while VEGFR2 and EPOR gene expressions were associated with favorable prognosis. Multivariate analysis confirmed high HIF2α protein expression as an independent risk factor. Prognostic validation of HIFs, LDH, EPOR and VEGFR2 in RNA-Seq data confirmed higher HIF1α gene expression in primary RCC as an adverse (p=0.07), whereas higher HIF2α and VEGFR2 expressions as favorable prognostic factors. HIF1α/HIF2α-index (HIF-index) proved to be an independent prognostic factor in both the discovery and the TCGA cohort. PATIENTS AND

methodsExpressions of HIF1α and HIF2α as well as their 7 target genes were analysed on the mRNA and protein level in 59 non-metastatic ccRCCs (nmRCC), 40 bone metastatic primary ccRCCs (mRCC) and 55 corresponding bone metastases. Results were validated in 399 ccRCCs from the TCGA project.

conclusionsWe identified HIF2α protein as an independent marker of the metastatic potential of ccRCC, however, unlike HIF1α, increased HIF2α expression is a favorable prognostic factor. The HIF-index incorporated these two markers into a strong prognostic biomarker of ccRCC.

Indexed as

AdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsBiomarkers, TumorBone NeoplasmsCarcinoma, Renal CellDisease-Free SurvivalEndothelial PAS Domain-Containing Protein 1FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsMaleBasic Helix-Loop-Helix ProteinsBiomarkers, TumorEndothelial PAS Domain-Containing Protein 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitRNA, Messengerbone metastasishypoxia inducible factorprognosisrenal cell cancer

Identifiers

PMID27244898
PMCPMC5173118
OpenAlexW2399811522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.